Trial · NCT03630120
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
NCT03630120, Phase 2, Terminated, H. Lee Moffitt Cancer Center and Research Institute; results first posted 2021-01-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer. Trials, record NCT03630120. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03630120
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
- NCT number
- NCT03630120
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Conditions
- Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Poorly Differentiated Thyroid Gland Carcinoma
- Interventions
- Lenvatinib, Sorafenib, Cabozantinib, Vandetanib
- First posted
- 2018-08-14
- Last updated
- 2021-07-14
- Results first posted
- 2021-01-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Progressive Disease | 2 years | Median time-to-discontinuation (TTD) of treatment per study arm, due to Progressive Disease. |
| Primary | Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Intolerability | 2 years | Median time-to-discontinuation (TTD) of treatment per study arm, due to Intolerability. |
| Primary | Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Disease Related Death | 2 years | Median time-to-discontinuation (TTD) of treatment per study arm, due to Disease-related death at 2 years. |
| Secondary | Overall Response Rate (ORR) | Up to 48 months | The response rate will be estimated using binomial theory with Wilson's method for the 95% confidence interval. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter (LD). Stable Disease (SD): Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started. |
| Secondary | Progression-free Survival (PFS) | Up to 48 months | The median progression-free survival rates will be estimated from the Kaplan-Meier curve with the 95% confidence interval obtained from Greenwood's formula. Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
| Secondary | Overall Survival (OS) | Up to 48 months | The median overall survival rates will be estimated from the Kaplan-Meier curve with the 95% confidence interval obtained from Greenwood's formula. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Progressive Disease | 2 years | Data not collected. Only 3 participants remained on study treatment, and none for full length of trial. | ||
| PRIMARY | Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Intolerability | 2 years | Data not collected. Only 3 participants remained on study treatment, and none for full length of trial. | ||
| PRIMARY | Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Disease Related Death | 2 years | Data not collected. Only 3 participants remained on study treatment, and none for full length of trial. | ||
| SECONDARY | Overall Response Rate (ORR) | Up to 48 months | Data not collected. Only 3 participants remained on study treatment, and none for full length of trial. | ||
| SECONDARY | Progression-free Survival (PFS) | Up to 48 months | Data not collected. Only 3 participants remained on study treatment, and none for full length of trial. | ||
| SECONDARY | Overall Survival (OS) | Up to 48 months | Data not collected. Only 3 participants remained on study treatment, and none for full length of trial. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Standard of Care: DTC | 2 | |
| Overall Study | STARTED | Adaptive Care: DTC | 2 | |
| Overall Study | STARTED | Standard of Care: MTC | 1 | |
| Overall Study | STARTED | Adaptive Care: MTC | 1 | |
| Overall Study | COMPLETED | Standard of Care: DTC | 2 | |
| Overall Study | COMPLETED | Adaptive Care: DTC | 1 | |
| Overall Study | COMPLETED | Standard of Care: MTC | 0 | |
| Overall Study | COMPLETED | Adaptive Care: MTC | 0 | |
| Overall Study | NOT COMPLETED | Standard of Care: DTC | 0 | |
| Overall Study | NOT COMPLETED | Adaptive Care: DTC | 1 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Vascular disorders | Standard of Care: DTC | 1 | 2 | 2 |
| other | Hypertension | Vascular disorders | Adaptive Care: DTC | 0 | 2 | 0 |
| other | Hypertension | Vascular disorders | Standard of Care: MTC | 0 | 1 | 0 |
| other | Hypertension | Vascular disorders | Adaptive Care: MTC | 0 | 1 | 0 |
Source ClinicalTrials.gov
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Standard of Care: DTC | 0 | 2 |
| Total, all-cause mortality | Adaptive Care: DTC | 1 | 2 |
| Total, all-cause mortality | Standard of Care: MTC | 1 | 1 |
| Total, all-cause mortality | Adaptive Care: MTC | 1 | 1 |
| Total, other adverse events | Standard of Care: DTC | 1 | 2 |
| Total, other adverse events | Adaptive Care: DTC | 0 | 2 |
| Total, other adverse events | Standard of Care: MTC | 0 | 1 |
| Total, other adverse events | Adaptive Care: MTC | 0 | 1 |
| Total, serious adverse events | Standard of Care: DTC | 0 | 2 |
| Total, serious adverse events | Adaptive Care: DTC | 0 | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03630120
GET https://conductscience.org/api/trials/v1/NCT03630120/registered